{"id":922552,"date":"2025-12-26T17:47:11","date_gmt":"2025-12-26T22:47:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/"},"modified":"2025-12-26T17:47:11","modified_gmt":"2025-12-26T22:47:11","slug":"southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/","title":{"rendered":"Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)"},"content":{"rendered":"
\n

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Southpoint Capital Advisors LP (\u201cSouthpoint\u201d), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a \u201cCommon Share\u201d) of Fennec Pharmaceuticals Inc. (\u201cFennec\u201d), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis).<\/p>\n

The Common Shares were sold at a price of USD$7.50 per Common Share.<\/p>\n

Southpoint now exercises control or direction over an aggregate of 2.7 million Common Shares, and representing approximately 8% of the outstanding Common Shares (calculated on a fully diluted basis).<\/p>\n

Southpoint has disposed of the Common Shares for investment purposes. Depending on market and other conditions, Southpoint may change its beneficial ownership of, or control or direction over, Common Shares through market transactions, private agreements, treasury issuances, exercise of the Warrants or otherwise.<\/p>\n

This press release has been issued in order to comply with applicable securities legislation.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

\n
For further information: \r\nAnthony J. Buffalano III\r\nSouthpoint Capital Advisors LP\r\n1114 Avenue of the Americas, 22nd Floor\r\nNew York, NY 10036\r\nPhone: (212) 692-6356<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Southpoint Capital Advisors LP (\u201cSouthpoint\u201d), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a \u201cCommon Share\u201d) of Fennec Pharmaceuticals Inc. (\u201cFennec\u201d), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis). The Common Shares were sold at a price of USD$7.50 per Common Share. Southpoint now exercises control or direction over an aggregate of 2.7 million Common Shares, and representing approximately 8% of the outstanding Common Shares (calculated on a fully diluted basis). Southpoint has disposed of the Common Shares for investment purposes. … <\/p>\n
Continue reading “Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-922552","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSouthpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Southpoint Capital Advisors LP (\u201cSouthpoint\u201d), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a \u201cCommon Share\u201d) of Fennec Pharmaceuticals Inc. (\u201cFennec\u201d), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis). The Common Shares were sold at a price of USD$7.50 per Common Share. Southpoint now exercises control or direction over an aggregate of 2.7 million Common Shares, and representing approximately 8% of the outstanding Common Shares (calculated on a fully diluted basis). Southpoint has disposed of the Common Shares for investment purposes. … Continue reading "Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-26T22:47:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzQwNiM3MzM3MTYzIzIwODk4NTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)\",\"datePublished\":\"2025-12-26T22:47:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\\\/\"},\"wordCount\":167,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNzQwNiM3MzM3MTYzIzIwODk4NTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\\\/\",\"name\":\"Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNzQwNiM3MzM3MTYzIzIwODk4NTE=\",\"datePublished\":\"2025-12-26T22:47:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNzQwNiM3MzM3MTYzIzIwODk4NTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNzQwNiM3MzM3MTYzIzIwODk4NTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/","og_locale":"en_US","og_type":"article","og_title":"Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) - Market Newsdesk","og_description":"NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Southpoint Capital Advisors LP (\u201cSouthpoint\u201d), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a \u201cCommon Share\u201d) of Fennec Pharmaceuticals Inc. (\u201cFennec\u201d), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis). The Common Shares were sold at a price of USD$7.50 per Common Share. Southpoint now exercises control or direction over an aggregate of 2.7 million Common Shares, and representing approximately 8% of the outstanding Common Shares (calculated on a fully diluted basis). Southpoint has disposed of the Common Shares for investment purposes. … Continue reading \"Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-26T22:47:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzQwNiM3MzM3MTYzIzIwODk4NTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)","datePublished":"2025-12-26T22:47:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/"},"wordCount":167,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzQwNiM3MzM3MTYzIzIwODk4NTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/","name":"Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzQwNiM3MzM3MTYzIzIwODk4NTE=","datePublished":"2025-12-26T22:47:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzQwNiM3MzM3MTYzIzIwODk4NTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNzQwNiM3MzM3MTYzIzIwODk4NTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/southpoint-holdings-in-fennec-pharmaceuticals-inc-tsx-fenc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/922552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=922552"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/922552\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=922552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=922552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=922552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}